Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) with a report date of June 17, 2009, covering events occurring on June 11, 2009. The filing discloses the appointment of a new senior executive and the entry into a material definitive employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change is the appointment of Robert Dickey IV as Senior Vice President, effective June 11, 2009. Mr. Dickey brings over 12 years of biotech senior management experience and an 18-year background in investment banking. He had previously served as a consultant to the company since November 2008.
Management Commentary and Compensation Details
- Base Salary: $275,000 per year.
- Annual Bonus: Up to 25% of annual salary, at the Board's discretion.
- Stock Options: Four-year options to purchase 150,000 shares at an exercise price of $2.81 per share. Options vest monthly over four years.
- Change in Control: Options vest in full if a "Change in control" occurs after three months of employment.
- Termination Provisions:
- Standard involuntary termination (after six months): 25% of annual compensation plus 25% of prior year's bonus.
- Termination following a Change in Control: 1.5 times annual compensation plus 1.5 times prior year's bonus.
Investor Verification Checklist
- Verify the company name discrepancy between the request metadata (AIM Immunotech Inc.) and the filing (Hemispherx Biopharma, Inc.).
- Confirm the current stock price relative to the $2.81 option exercise price.
- Review the company's cash position to assess the ability to fund the new executive's salary and potential severance obligations.
- Check for any pending "Change in control" events that would trigger immediate option vesting.